$0.1870−$0.0110 (−5.56%) on the dayAs of the close; data may be delayed.
GCTK price, last 12 months
$204.00$0.1870
Daily closes over the last 260 trading sessions: −99.9%. Highest close $204.00 on , lowest $0.1870 on . Market data may be delayed.
Key stats
Previous close
$0.1980
Open
$0.2022
Day range
$0.1870 – $0.2326
52-week range
$0.1833 – $207.00
Volume
5.4K
Avg volume (20 days)
3.7M
Market cap
—
Performance
1W−17.5%
1M−84.7%
3M−98.2%
6M−98.8%
YTD−99.8%
1Y−99.9%
vs S&P 500, 1Y−105.1 pts
Technicals and fundamentals
About GLUCOTRACK INC NEW
GLUCOTRACK INC NEW
Listed on
NASDAQ
Market cap
—
Recent news about GCTK
Chart GCTK with indicators, scan for setups and get alerts
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
A full GCTK chart with indicator overlays, pattern markers and daily, weekly or intraday bars.
Scans of a whole index or list with 72 named conditions, 26 chart setups or a formula of your own.
Alerts and notifications when one fires on a stock you watch, on delayed market data.
Daily range (ATR)131.1%average true range, % of price
52w low $0.183352w high $207.00
Where price sits today against its own history. A description, not a forecast.
Valuation
P/E (trailing)—
P/E (forward)—
PEG—
Price / sales—
Price / book−0.17
EV / EBITDA—
Company figures as of Oct 29, 2026.
Dividends & splits
No dividends on record.
Splits
Oct 26, 20261-for-2 (reverse)
Aug 31, 20261-for-15 (reverse)
Jun 16, 20251-for-60 (reverse)
Seasonality
-40.4
J
-13.6
F
-42.8
M
+18.9
A
-14.3
M
-21.2
J
-0.8
J
+1.0
A
-1.1
S
-29.3
O
-16.1
N
+2.8
D
Average return in each calendar month, Apr 30, 2022 to Oct 31, 2026. 5 years is 5 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
Year by year
Year
J
F
M
A
M
J
J
A
S
O
N
D
Year
2026
−51
−19
−58
+31
−23
−52
+50
−41
−61
−75
−99%
2025
−83
−72
−52
−1
−25
−23
+3
−31
+56
−2
+5
−43
−99%
2024
−20
+43
+10
+62
−13
−13
−40
+117
−7
−30
−86
+54
−71%
2023
−9
−7
−72
+24
−5
−14
−8
−18
+1
−31
+30
+11
−81%
2022
−21
−6
−4
−7
−22
+6
−8
−14
−11
−61%
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
Financials
As reported in the company's SEC filings. Latest: Q2 FY2026, ended Jun 30, 2026.
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
Glucotrack is gaining access to a Nasdaq listing through the combination and will continue operating its CBGM business as a subsidiary of the combined entity, providing stability and growth opportunities through the merger with Lōkahi Therapeutics.
The completion of the strategic business combination provides Glucotrack with public market access, capital-efficient operations, and integration with Lōkahi's ai²-driven platform. The company gains access to a broader asset sourcing and development framework while maintaining its CBGM technology as a focused subsidiary, positioning it for scalable growth and strategic opportunities.
Company achieved significant regulatory milestone with FDA IDE submission, demonstrated scientific validation through peer-reviewed publications showing 6.8% MARD accuracy over 240 days, reduced net losses year-over-year, decreased debt obligations, and is on track for clinical trial initiation in H2 2026. However, positive sentiment is tempered by declining cash position ($3.9M from $7.4M) and limited runway into early Q3 2026, creating near-term funding pressure.
The company achieved a significant regulatory milestone by submitting its IDE application to the FDA, which is a critical step toward clinical evaluation and commercialization. The announcement demonstrates substantial progress in preclinical development and positions the company closer to bringing an innovative implantable glucose monitoring solution to market. The technology offers meaningful advantages over existing wearable solutions, supporting positive investor sentiment.
Company demonstrated operational progress with improved net loss ($19.4M vs $22.6M), strengthened IP portfolio with three new patents, secured $4.0M in funding, and is advancing toward key regulatory milestones (IDE submission Q2 2026, clinical trials H2 2026). Cash position improved and company states existing cash is sufficient to fund 2026 operations through IDE submission and trial initiation.
The article highlights Glucotrack's successful transition from a preclinical to a clinical stage company, the advancement of its continuous blood glucose monitoring technology, the strengthening of its leadership team, and the securing of funding to support its growth plans, all of which indicate positive progress for the company.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.